Logo image of BNN.DE

BRAIN BIOTECH AG (BNN.DE) Stock Fundamental Analysis

FRA:BNN - Deutsche Boerse Ag - DE0005203947 - Common Stock - Currency: EUR

2.35  -0.03 (-1.26%)

Fundamental Rating

2

Overall BNN gets a fundamental rating of 2 out of 10. We evaluated BNN against 61 industry peers in the Chemicals industry. BNN has a bad profitability rating. Also its financial health evaluation is rather negative. BNN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BNN had negative earnings in the past year.
In the past year BNN has reported a negative cash flow from operations.
In the past 5 years BNN always reported negative net income.
BNN had a negative operating cash flow in each of the past 5 years.
BNN.DE Yearly Net Income VS EBIT VS OCF VS FCFBNN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.58%, BNN is doing worse than 79.37% of the companies in the same industry.
BNN has a Return On Equity of -121.45%. This is amonst the worse of the industry: BNN underperforms 87.30% of its industry peers.
Industry RankSector Rank
ROA -15.58%
ROE -121.45%
ROIC N/A
ROA(3y)-10.89%
ROA(5y)-10.5%
ROE(3y)-49.48%
ROE(5y)-41.57%
ROIC(3y)N/A
ROIC(5y)N/A
BNN.DE Yearly ROA, ROE, ROICBNN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

BNN has a Gross Margin of 55.94%. This is amongst the best in the industry. BNN outperforms 87.30% of its industry peers.
BNN's Gross Margin has been stable in the last couple of years.
BNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.53%
GM growth 5Y-0.08%
BNN.DE Yearly Profit, Operating, Gross MarginsBNN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

More info and screens

3

2. Health

2.1 Basic Checks

BNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BNN has more shares outstanding
BNN has a better debt/assets ratio than last year.
BNN.DE Yearly Shares OutstandingBNN.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
BNN.DE Yearly Total Debt VS Total AssetsBNN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

BNN has a Debt/Equity ratio of 4.93. This is a high value indicating a heavy dependency on external financing.
BNN has a Debt to Equity ratio of 4.93. This is amonst the worse of the industry: BNN underperforms 90.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.93
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.52%
BNN.DE Yearly LT Debt VS Equity VS FCFBNN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M 40M

2.3 Liquidity

BNN has a Current Ratio of 1.87. This is a normal value and indicates that BNN is financially healthy and should not expect problems in meeting its short term obligations.
BNN has a better Current ratio (1.87) than 60.32% of its industry peers.
A Quick Ratio of 1.87 indicates that BNN should not have too much problems paying its short term obligations.
BNN has a better Quick ratio (1.87) than 79.37% of its industry peers.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.87
BNN.DE Yearly Current Assets VS Current LiabilitesBNN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

BNN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.08%.
The Revenue has been growing slightly by 1.07% in the past year.
The Revenue has been growing slightly by 6.74% on average over the past years.
EPS 1Y (TTM)-49.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.44%
Revenue 1Y (TTM)1.07%
Revenue growth 3Y12.27%
Revenue growth 5Y6.74%
Sales Q2Q%2.47%

3.2 Future

The Earnings Per Share is expected to grow by 35.77% on average over the next years. This is a very strong growth
BNN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.13% yearly.
EPS Next Y92.98%
EPS Next 2Y48.97%
EPS Next 3Y23.36%
EPS Next 5Y35.77%
Revenue Next Year12.1%
Revenue Next 2Y11.4%
Revenue Next 3Y9.5%
Revenue Next 5Y5.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BNN.DE Yearly Revenue VS EstimatesBNN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
BNN.DE Yearly EPS VS EstimatesBNN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.2 -0.2 0.4 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNN. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 37.23 indicates a quite expensive valuation of BNN.
Based on the Price/Forward Earnings ratio, BNN is valued a bit more expensive than the industry average as 63.49% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, BNN is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 37.23
BNN.DE Price Earnings VS Forward Price EarningsBNN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNN.DE Per share dataBNN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

BNN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BNN's earnings are expected to grow with 23.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.97%
EPS Next 3Y23.36%

More info and screens

0

5. Dividend

5.1 Amount

BNN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAIN BIOTECH AG

FRA:BNN (3/7/2025, 7:00:00 PM)

2.35

-0.03 (-1.26%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-26 2025-02-26
Earnings (Next)05-28 2025-05-28
Inst Owners15.54%
Inst Owner ChangeN/A
Ins Owners53.72%
Ins Owner ChangeN/A
Market Cap51.35M
Analysts84.44
Price Target6.84 (191.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.38%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)33.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)-3.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 37.23
P/S 0.92
P/FCF N/A
P/OCF N/A
P/B 4.98
P/tB 4.98
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)0.06
Fwd EY2.69%
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS2.55
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.58%
ROE -121.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.94%
FCFM N/A
ROA(3y)-10.89%
ROA(5y)-10.5%
ROE(3y)-49.48%
ROE(5y)-41.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.53%
GM growth 5Y-0.08%
F-Score2
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 4.93
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.87
Quick Ratio 1.87
Altman-Z N/A
F-Score2
WACC6.52%
ROIC/WACCN/A
Cap/Depr(3y)77.56%
Cap/Depr(5y)65.96%
Cap/Sales(3y)6.63%
Cap/Sales(5y)6.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.44%
EPS Next Y92.98%
EPS Next 2Y48.97%
EPS Next 3Y23.36%
EPS Next 5Y35.77%
Revenue 1Y (TTM)1.07%
Revenue growth 3Y12.27%
Revenue growth 5Y6.74%
Sales Q2Q%2.47%
Revenue Next Year12.1%
Revenue Next 2Y11.4%
Revenue Next 3Y9.5%
Revenue Next 5Y5.13%
EBIT growth 1Y-73.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year409.12%
EBIT Next 3Y146.14%
EBIT Next 5Y84.87%
FCF growth 1Y36.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.97%
OCF growth 3YN/A
OCF growth 5YN/A